Blau Farmaceutica SA BLAU3
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- BRL 10.07
- Day Range
- BRL 9.96–10.52
- 52-Week Range
- BRL 9.29–22.56
- Bid/Ask
- BRL 10.11 / BRL 10.40
- Market Cap
- BRL 1.82 Bil
- Volume/Avg
- 369,400 / 329,053
Key Statistics
- Price/Earnings (Normalized)
- 7.29
- Price/Sales
- 1.32
- Dividend Yield (Trailing)
- 3.10%
- Dividend Yield (Forward)
- 3.10%
- Total Yield
- 4.10%
Company Profile
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,070
- Website
- https://www.blau.com
Comparables
Valuation
|
Metric
|
BLAU3
|
NYKD
|
TLX
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.29 | — | 116.53 |
Price/Book Value | 0.89 | 2.51 | 32.17 |
Price/Sales | 1.32 | 29.40 | 9.51 |
Price/Cash Flow | 9.50 | — | 197.78 |
Price/Earnings
BLAU3
NYKD
TLX
Financial Strength
|
Metric
|
BLAU3
|
NYKD
|
TLX
|
|---|---|---|---|
Quick Ratio | 2.70 | 7.91 | 1.19 |
Current Ratio | 4.63 | 8.04 | 1.43 |
Interest Coverage | 9.67 | −235.75 | 1.15 |
Quick Ratio
BLAU3
NYKD
TLX
Profitability
|
Metric
|
BLAU3
|
NYKD
|
TLX
|
|---|---|---|---|
Return on Assets (Normalized) | 5.55% | −19.18% | 3.71% |
Return on Equity (Normalized) | 7.95% | −26.31% | 11.73% |
Return on Invested Capital (Normalized) | 5.78% | −30.96% | 18.08% |
Return on Assets
BLAU3
NYKD
TLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Ptmjlcrjpn | Wrll | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Dvngzpvtl | Bwscnj | $69.1 Bil | |
HLN
| Haleon PLC ADR | Lyhrsbpt | Vzy | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Nncqzqfd | Fhwwq | $15.7 Bil | |
VTRS
| Viatris Inc | Sqbjpzk | Lfghb | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Xxrtlny | Pgmrj | $12.4 Bil | |
CTLT
| Catalent Inc | Jxwrcqczz | Xtwmnqn | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Zplkxsrd | Rfm | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Dkhnybl | Qkqc | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xgyjxkk | Dccwcd | $3.5 Bil |